

# Corrado CaracÃ²

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6141538/publications.pdf>

Version: 2024-02-01

54  
papers

2,653  
citations

201674

27  
h-index

182427

51  
g-index

59  
all docs

59  
docs citations

59  
times ranked

4424  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529.	1.6	419
2	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	4.6	318
3	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
4	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1713-1742.	6.4	159
5	Human Melanoma Metastases Express Functional CXCR4. <i>Clinical Cancer Research</i> , 2006, 12, 2427-2433.	7.0	114
6	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptaseâ€“Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
7	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	4.4	85
8	Sentinel Node Biopsy in Thin and Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 2780-2786.	1.5	72
9	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008842.	4.6	72
10	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. <i>Journal of Clinical Oncology</i> , 2001, 19, 1437-1443.	1.6	63
11	Metastatic eccrine porocarcinoma: report of a case and review of the literature. <i>World Journal of Surgical Oncology</i> , 2011, 9, 32.	1.9	63
12	Locoregional Spread of Cutaneous Melanoma: Sonography Findings. <i>American Journal of Roentgenology</i> , 2010, 194, 735-745.	2.2	58
13	Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. <i>BMC Cancer</i> , 2013, 13, 564.	2.6	53
14	Nonsentinel Lymph Node Status in Patients With Cutaneous Melanoma: Results From a Multi-Institution Prognostic Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 935-941.	1.6	49
15	Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 271-279.	1.5	44
16	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1405206.	4.6	43
17	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> , 2009, 9, 352.	2.6	42
18	Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. <i>World Journal of Surgical Oncology</i> , 2012, 10, 275.	1.9	42

#	ARTICLE	IF	CITATIONS
19	Number of Excised Lymph Nodes as a Quality Assurance Measure for Lymphadenectomy in Melanoma. <i>JAMA Surgery</i> , 2014, 149, 700.	4.3	42
20	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon- $\gamma$ 2b treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 76.	4.4	39
21	Laparoscopic cholecystectomy for melanoma metastatic to the gallbladder: is it an adequate surgical procedure? Report of a case and review of the literature. <i>World Journal of Surgical Oncology</i> , 2007, 5, 141.	1.9	37
22	Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. <i>Journal of Translational Medicine</i> , 2017, 15, 82.	4.4	35
23	Renal cell carcinoma with solitary toe metastasis. <i>International Journal of Urology</i> , 2005, 12, 401-404.	1.0	33
24	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	4.4	31
25	Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. <i>Cancer Biology and Therapy</i> , 2010, 9, 423-429.	3.4	30
26	Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 131.	4.4	30
27	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. <i>European Journal of Cancer</i> , 2007, 43, 137-143.	2.8	28
28	Malignant melanoma developing in an area of hereditary palmoplantar keratoderma (Mal De Meleda). <i>Journal of Surgical Oncology</i> , 2003, 84, 229-233.	1.7	24
29	Soluble interleukin-2 receptor in stage III melanoma. <i>Cytokine</i> , 2006, 33, 150-155.	3.2	24
30	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019, 19, 772.	2.6	24
31	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019, 17, 289.	4.4	24
32	Previously Reported Sonographic Appearances of Regional Melanoma Metastases Are Not Likely Due to Necrosis. <i>Journal of Ultrasound in Medicine</i> , 2011, 30, 1041-1049.	1.7	23
33	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon- $\gamma$ in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	4.4	21
34	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. <i>BMC Cancer</i> , 2006, 6, 266.	2.6	19
35	Prognostic impact of regression in patients with primary cutaneous melanoma $\geq 1$ mm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	1.2	19
36	Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. <i>World Journal of Surgical Oncology</i> , 2013, 11, 36.	1.9	18

#	ARTICLE	IF	CITATIONS
37	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Journal of Translational Medicine, 2015, 13, 37.	4.4	15
38	The role of spectrophotometry in the diagnosis of melanoma. BMC Dermatology, 2010, 10, 5.	2.1	13
39	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. Journal of Investigative Dermatology, 2016, 136, 1917-1920.	0.7	13
40	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. Journal of Clinical Oncology, 2012, 30, 8573-8573.	1.6	13
41	Surgical Management of Sentinel Lymph Node Biopsy Outside Major Nodal Basin in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2014, 21, 300-305.	1.5	12
42	Resection in the popliteal fossa for metastatic melanoma. World Journal of Surgical Oncology, 2007, 5, 8.	1.9	11
43	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. Journal of Clinical Medicine, 2020, 9, 2430.	2.4	10
44	Intermediate dose recombinant interferon- $\gamma$ as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer, 2000, 89, 1490-1494.	4.1	9
45	Electrochemotherapy in melanoma patients: a single institution experience. Melanoma Management, 2015, 2, 127-132.	0.5	7
46	Clinicopathologic features and surgical management of primary umbilical melanoma: a case series. BMC Research Notes, 2015, 8, 147.	1.4	5
47	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019,) Tj ETQq1.1 0.784314 rgBT / 4.4 5	4.4	5
48	Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. International Journal of Oncology, 2003, 22, 1209-15.	3.3	5
49	Half forehead reconstruction with a single rotational scalp flap for dermatofibrosarcoma protuberans treatment. World Journal of Surgical Oncology, 2012, 10, 78.	1.9	3
50	Vemurafenib beyond progression in a patient with metastatic melanoma. Anti-Cancer Drugs, 2015, 26, 464-468.	1.4	2
51	The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. BMC Cancer, 2021, 21, 8.	2.6	2
52	Mobile hospital rooms to fight melanoma. Melanoma Research, 2001, 11, 83-84.	1.2	1
53	Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma. Journal of Translational Medicine, 2014, 12, P1.	4.4	0
54	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. Journal of Translational Medicine, 2022, 20, 200.	4.4	0